Zydus Lifesciences Ltd on Tuesday reported a 14.6 per cent growth in consolidated net profit at ₹1,592.9 crore for the fourth quarter ended March 31, 2026 riding on strong growth in the consumer wellness vertical.

The company, which had posted a profit of ₹1,390.5 crore in the year-ago period, said its board has approved buyback of equity shares for an aggregate amount up to ₹1,100 crore at a price of ₹1,150 per share.

Revenue from operations in the quarter stood at ₹7,587 crore as against ₹6,527.9 crore in the year-ago period, Zydus Lifesciences said in a regulatory filing.

The company said its pharma business clocked a revenue of ₹5,643.6 crore in the fourth quarter, as against ₹5,380.4 crore a year ago, up 4.9 per cent. The consumer wellness vertical registered revenue of ₹1,463.3 crore, as against ₹908.1 crore.

The board also recommended a final dividend of ₹1 per equity share of ₹1 each, subject to approval of shareholders, it added.

In FY26, the net profit rose 15 per cent to ₹5,456.4 crore, as against ₹4,745.1 crore a year ago. Revenue from operations was at ₹27,148.4 crore, as against ₹23,241.5 crore.

"We closed FY26 on a strong note, delivering on our commitments, both on revenue growth and profitability," Zydus Lifesciences Managing Director Sharvil Patel said.

On the outlook, he said, "We are confident our pipeline will drive overall growth visibility, while future growth engines begin to deliver. Our near -term priorities are clear -- maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly."

The company's "strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further", Patel noted.

Published on May 19, 2026